Home » BreastSentry

BreastSentry Can Identify Women at Greater Risk for Breast Cancer

BreastSentry measures the levels of two bio-markers, proneurotensin (pro-NT) and proenkephalin (pro-ENK), which are highly predictive of a woman’s risk for developing breast cancer. Elevated levels of pro-NT and decreased levels of pro-ENK are strong, independent risk factors for the development of breast cancer (1-5). BreastSentry provides women with additional information about breast health beyond mammography. Women with elevated BreastSentry scores may need to be referred for advanced imaging tests, such as breast MRI or Ultrasound in addition to a screening mammogram.

BreastSentry Patient Selection Criteria

BreastSentry is for any woman who needs further evaluation of breast cancer risk. 

The BreastSentry Test is intended for use in women without a personal history of breast cancer. Patients with a known history of impaired renal function are not candidates for the BreastSentry test.

Breast Cancer: Why Early Detection Matters graphic with woman smiling  underneath the stats: early detection has a 5 year survival rate 99% while late detection's 5 year survival rate is 28%.

Breast Sentry Patient Eligibility Form

  • This field is for validation purposes and should be left unchanged.

References

  1. Melander O, Maisel AS, Almgren P, et al. Plasma proneurotensin and incidence of diabetes, cardiovascular disease, breast cancer, and mortality. JAMA 2012;308:1469 
  2. O, Belting M, Manjer J, et al. Validation of plasma proneurotensin as a novel biomarker for the prediction of incident breast cancer.  Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1672-6. 
  3. Melander O, Orho-Melander M, Manjer J, et al. Stable Peptide of the Endogenous Opioid Enkephalin Precursor and Breast Cancer Risk. J Clin Oncol. 2015 Aug 20;33(24):2632-8 
  4. Dupouy S, Mourra N, Doan VK, et al. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie 2011;93:1369–78 
  5. Dupouy S, Viardot-Foucault V, Alifano M,  et al.  The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. PLoS ONE 2009; 4(1): e4223. https://doi.org/10.1371/journal.pone.0004223 ​


    *Cancer.gov/types/breast/mammograms-fact-sheet (2021)

BreastSentry™  was developed and its performance characteristics determined by Stage Zero Life Sciences, Inc.  It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

The BreastSentry™ test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications.